Your browser doesn't support javascript.
loading
GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals.
Ter Huurne, Menno; Parker, Benjamin L; Liu, Ning Qing; Qian, Elizabeth Ling; Vivien, Celine; Karavendzas, Kathy; Mills, Richard J; Saville, Jennifer T; Abu-Bonsrah, Dad; Wise, Andrea F; Hudson, James E; Talbot, Andrew S; Finn, Patrick F; Martini, Paolo G V; Fuller, Maria; Ricardo, Sharon D; Watt, Kevin I; Nicholls, Kathy M; Porrello, Enzo R; Elliott, David A.
Afiliación
  • Ter Huurne M; Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, VIC, Australia; The Novo Nordisk Foundation Centre for Stem Cell Medicine (reNEW), Murdoch Children's Research Institute, Melbourne, VIC, Australia; Department of Paediatrics, University of Melbourne, Melbourne, VIC, Au
  • Parker BL; Department of Anatomy and Physiology, University of Melbourne, Melbourne, VIC, Australia; Centre for Muscle Research, University of Melbourne, Melbourne, VIC, Australia.
  • Liu NQ; Department of Hematology, Erasmus Medical Center (MC) Cancer Institute, Rotterdam, the Netherlands.
  • Qian EL; Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, VIC, Australia.
  • Vivien C; Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, VIC, Australia.
  • Karavendzas K; Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, VIC, Australia.
  • Mills RJ; Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, VIC, Australia; The Novo Nordisk Foundation Centre for Stem Cell Medicine (reNEW), Murdoch Children's Research Institute, Melbourne, VIC, Australia; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Austral
  • Saville JT; Genetics and Molecular Pathology, SA Pathology at Women's and Children's Hospital and Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.
  • Abu-Bonsrah D; Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, VIC, Australia.
  • Wise AF; Department of Pharmacology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
  • Hudson JE; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Talbot AS; Department of Nephrology, The Royal Melbourne Hospital and Department of Medicine (RMH), University of Melbourne, Parkville, VIC, Australia.
  • Finn PF; Rare Diseases Research, Moderna Inc., 200 Technology Sq., Cambridge, MA, USA.
  • Martini PGV; Rare Diseases Research, Moderna Inc., 200 Technology Sq., Cambridge, MA, USA.
  • Fuller M; Genetics and Molecular Pathology, SA Pathology at Women's and Children's Hospital and Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.
  • Ricardo SD; Department of Pharmacology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
  • Watt KI; Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, VIC, Australia; The Novo Nordisk Foundation Centre for Stem Cell Medicine (reNEW), Murdoch Children's Research Institute, Melbourne, VIC, Australia; Department of Anatomy and Physiology, University of Melbourne, Melbour
  • Nicholls KM; Department of Pharmacology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
  • Porrello ER; Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, VIC, Australia; The Novo Nordisk Foundation Centre for Stem Cell Medicine (reNEW), Murdoch Children's Research Institute, Melbourne, VIC, Australia; Department of Anatomy and Physiology, University of Melbourne, Melbour
  • Elliott DA; Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, VIC, Australia; The Novo Nordisk Foundation Centre for Stem Cell Medicine (reNEW), Murdoch Children's Research Institute, Melbourne, VIC, Australia; Melbourne Centre for Cardiovascular Genomics and Regenerative Medicine
Am J Hum Genet ; 110(9): 1600-1605, 2023 09 07.
Article en En | MEDLINE | ID: mdl-37607539
ABSTRACT
Recent studies in non-human model systems have shown therapeutic potential of nucleoside-modified messenger RNA (modRNA) treatments for lysosomal storage diseases. Here, we assessed the efficacy of a modRNA treatment to restore the expression of the galactosidase alpha (GLA), which codes for α-Galactosidase A (α-GAL) enzyme, in a human cardiac model generated from induced pluripotent stem cells (iPSCs) derived from two individuals with Fabry disease. Consistent with the clinical phenotype, cardiomyocytes from iPSCs derived from Fabry-affected individuals showed accumulation of the glycosphingolipid Globotriaosylceramide (GB3), which is an α-galactosidase substrate. Furthermore, the Fabry cardiomyocytes displayed significant upregulation of lysosomal-associated proteins. Upon GLA modRNA treatment, a subset of lysosomal proteins were partially restored to wild-type levels, implying the rescue of the molecular phenotype associated with the Fabry genotype. Importantly, a significant reduction of GB3 levels was observed in GLA modRNA-treated cardiomyocytes, demonstrating that α-GAL enzymatic activity was restored. Together, our results validate the utility of iPSC-derived cardiomyocytes from affected individuals as a model to study disease processes in Fabry disease and the therapeutic potential of GLA modRNA treatment to reduce GB3 accumulation in the heart.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Fabry / Células Madre Pluripotentes Inducidas Límite: Humans Idioma: En Revista: Am J Hum Genet Año: 2023 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Fabry / Células Madre Pluripotentes Inducidas Límite: Humans Idioma: En Revista: Am J Hum Genet Año: 2023 Tipo del documento: Article País de afiliación: Australia